#LIBTAYO - Twitter Hashtag

5 days ago

💊 Regeneron’s LIBTAYO Recommended for Updated EU Dosing Regimen A new European recommendation marks progress for LIBTAYO’s treatment regimen. 👉 https://t.co/xgj2PtAAUg #Regeneron #LIBTAYO #Oncology

cGxPWire's tweet photo. 💊 Regeneron’s LIBTAYO Recommended for Updated EU Dosing Regimen

A new European recommendation marks progress for LIBTAYO’s treatment regimen.

👉 https://t.co/xgj2PtAAUg

#Regeneron #LIBTAYO #Oncology https://t.co/qlJhN7xQwV

0

33

Dermatology Times @DermTimesNow

about 1 year ago

❗Regeneron’s #cemiplimab #Libtayo earns EU backing as the first adjuvant immunotherapy for high-risk #CSCC post-surgery and radiation, cutting recurrence risk by 68% in trials. https://t.co/08ktBT4e4t #SkinCancer #DermTwitter

0

3

0

1

314

Dermatology Times @DermTimesNow

about 1 year ago

❗FDA approves #cemiplimab (#Libtayo) as the first adjuvant immunotherapy for high-risk #CSCC post-surgery/radiation. https://t.co/S35trhT30t #DermTwitter

0

7

1

0

370

Immuneering Corp

@Immuneering

over 1 year ago

Today $IMRX announced a clinical supply agreement with @Regeneron, supporting evaluation of IMM-1-104 in combo with #Libtayo in patients with #RASmutant #NSCLC. Read the press release here: https://t.co/oQ4KZPPMyL

Immuneering's tweet photo. Today $IMRX announced a clinical supply agreement with @Regeneron, supporting evaluation of IMM-1-104 in combo with #Libtayo in patients with #RASmutant #NSCLC.
Read the press release here: https://t.co/oQ4KZPPMyL https://t.co/oyeYjCDuIV

1

6

1

0

366

Oncology Tube

@oncologytube

almost 3 years ago

🔬 @DrNeilGross discusses groundbreaking Phase 2 Trial of #Libtayo for CSCC at #ESMO2023. Key findings: 89% survival at 1 year, 51% achieved pathologic complete response, and more. 🩺 Watch the interview here: [video]https://t.co/6V9vxrMOUK #hncsm @AHNSinfo @MDAndersonNews

oncologytube's tweet photo. 🔬 @DrNeilGross discusses groundbreaking Phase 2 Trial of #Libtayo for CSCC at #ESMO2023. Key findings: 89% survival at 1 year, 51% achieved pathologic complete response, and more. 🩺 Watch the interview here: [video]https://t.co/6V9vxrMOUK #hncsm @AHNSinfo @MDAndersonNews https://t.co/LpPXUnDwWN

1

7

1

0

2K

3PrimeAnalytica

@3primeAnalytica

about 3 years ago

Where would #Sanofi be without $REGN's #Dupixent? Imagine if they took it away like #Libtayo. Market didn't buy the optimism in the PR this morning, even with Paul Hudson shouting #AI. Still amazed by #Dupixent's continued growth after +6 yrs in the market...and this is without COPD.

3primeAnalytica's tweet photo. Where would #Sanofi be without $REGN's #Dupixent?

Imagine if they took it away like #Libtayo.

Market didn't buy the optimism in the PR this morning, even with Paul Hudson shouting #AI. Still amazed by #Dupixent's continued growth after +6 yrs in the market...and this is without COPD.

1

2

0

815

Course5 Life Sciences @Course5_LifeSci

over 3 years ago

#Regeneron’s #Libtayo in combination with chemotherapy approved by the EC for the first-line treatment of adult patients with advanced #NSCLC with ≥ 1% PD-L1 expression based on the #Phase 3 EMPOWER-Lung 3 trial. https://t.co/peR0TUgWS8

0

2

1

0

304

Provectus Biopharmaceuticals, Inc.

@ProvectusBio

almost 4 years ago

31/ #yervoy anti-CTLA-4, #keytruda, #opdivo, #libtayo (anti-PD-1), #bavencio, #tecentriq, #imfinzi (anti-PD-L1), #yervoy+opdivo (CTLA-4+PD-1), #opduolag (PD-1+LAG-3) are all non-specific (non-tumor-specific) immunotherapies.

2

0

331

ipharmacenter @ipharmacenter

almost 4 years ago

#Libtayo was approved for advanced or recurrent #cervicalcancer in #Japan. https://t.co/A7ORHxpDeC #製薬 #健康 #健康管理 #ニュース #日本 #Pharma #pharmaceutical #healthcare #globalhealth #Patientcare #news #media #digitalhealth #cancer #oncology #womenhealth #women

0

2

0

56

Karolina WP @Kto72102356

almost 4 years ago

Komisja Europejska zatwierdziła rozszerzone zastosowanie #Libtayo (cemiplimab) w monoterapii w leczeniu dorosłych pacjentek z nawracającym lub przerzutowym rakiem szyjki macicy i progresją choroby w trakcie, lub po chemioterapii opartej na platynie. Stanowi immunoterapię II rzutu

Regeneron @Regeneron

almost 4 years ago

#BREAKING: The European Commission approved our #immunotherapy as a treatment option for recurrent or metastatic #cervicalcancer in Europe.

Regeneron's tweet photo. #BREAKING: The European Commission approved our #immunotherapy as a treatment option for recurrent or metastatic #cervicalcancer in Europe.

0

17

1

0

2

1

0

Course5 Life Sciences @Course5_LifeSci

almost 4 years ago

#Regeneron’s #Libtayo approved by the EC as the first immunotherapy in second line recurrent or metastatic cervical cancer irrespective of PD-L1 expression level or tumor histology. https://t.co/sZnRxk8N9T

0

2

3

0

1stOncology @1stOncology

over 4 years ago

#INOVIO Announces Survival Results for #INO5401 plus #INO9012 in Combination with #Libtayo (#Cemiplimab) in Patients with Newly Diagnosed #GBM at #ASCO22 $INO https://t.co/dt23unOJxd

0

6

1

0

LARVOL

@Larvol

over 4 years ago

#Libtayo: Regulatory decision in US for 1L #NSCLC in combination with chemotherapy in H2 2022 For more real-time high-impact news visit https://t.co/AoToSB2Hha and request a demo of PULSE.

Larvol's tweet photo. #Libtayo: Regulatory decision in US for 1L #NSCLC in combination with chemotherapy in H2 2022
For more real-time high-impact news visit https://t.co/AoToSB2Hha and request a demo of PULSE. https://t.co/VXbxnNorDv

0

3

0

Joanne Fagg @ByJoFagg

over 4 years ago

My January #Pdufa tracker includes: 👍 #Vabysmo $RHHBY and #Kimmtrak $IMCR 👎 #Gefapixant $MRK and #Somatrogon $PFE $OPK 😣#Libtayo $REGN $SNY, #Olumiant $LLY https://t.co/IsQkNDg8W4 Here's a look ahead to February's #FDA approval decisions and adcoms: https://t.co/fyOjGpNmu5

0

6

2

0

LARVOL

@Larvol

about 5 years ago

New #PrecisionMedicine highlights added to the VERI database last week: @FDA reviewing @genetech's #Tecentriq for treatment of #NSCLC, #Libtayo trial proves successful, ends early for treatment of NSCLC and much more. Access these stories and more: https://t.co/yqYLzhtoa3

Larvol's tweet photo. New #PrecisionMedicine highlights added to the VERI database last week: @FDA reviewing @genetech's #Tecentriq for treatment of #NSCLC, #Libtayo trial proves successful, ends early for treatment of NSCLC and much more.

Access these stories and more: https://t.co/yqYLzhtoa3 https://t.co/fmHEuwKbMN

0

4

1

0

Biotech Jim

@JamesEKrause

about 5 years ago

@Xx10xX14 #Libtayo is here to stay. It will be a backbone therapy for much of the current oncology pipeline from $REGN. Today's news with L in first-line advanced non-small cell lung cancer is solid. https://t.co/xw9xm635Cy

0

2

0

Capital @MagazineCapital

about 5 years ago

Cancer du poumon : le #Libtayo de #Sanofi suscite l’espoir https://t.co/IP7Yj1azRm

0

LARVOL

@Larvol

over 5 years ago

European Commission has approved #Libtayo in advanced #NSCLC with ≥50% PD-L1 expression. For all the recent #biomarker data visit VERI https://t.co/qQ2y0deYrC